European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment

G. A. Lee; S. Aktaa; E. Baker; C. P. Gale; Israa F. Yaseen; G. Gulati; R. Asteggiano; S. Szmit; A. Cohen-Solal; A. Abdin; W. Jurczak; P. Garrido Lopez; A. L. Sverdlov; C. G. Tocchetti; A. Barac; I. Parrini; P. Zamorano; Z. Iakobishvili; R. Pudil; L. Badimon; A. M. Kirby; A. H. Blaes; D. Farmakis; G. Curigliano; R. Stephens; A. R. Lyon; T. Lopez-Fernandez

doi:10.1093/ehjqcco/qcac070

European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment

G. A. Lee, S. Aktaa, E. Baker, C. P. Gale, Israa F. Yaseen, G. Gulati, R. Asteggiano, S. Szmit, A. Cohen-Solal, A. Abdin, W. Jurczak, P. Garrido Lopez, A. L. Sverdlov, C. G. Tocchetti, A. Barac, I. Parrini, P. Zamorano, Z. Iakobishvili, R. Pudil, L. BadimonA. M. Kirby, A. H. Blaes, D. Farmakis, G. Curigliano, R. Stephens, A. R. Lyon, T. Lopez-Fernandez

Research output: Contribution to journal › Review article › peer-review

17 Scopus citations

Abstract

Aims To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. Methods and results We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy. Conclusion We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.

Original language	English (US)
Pages (from-to)	1-7
Number of pages	7
Journal	European Heart Journal - Quality of Care and Clinical Outcomes
Volume	9
Issue number	1
DOIs	https://doi.org/10.1093/ehjqcco/qcac070
State	Published - Jan 1 2023

Bibliographical note

Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

Keywords

Assessment
Cancer therapy-related cardiovascular toxicity
Cardio-oncology
Outcomes
Quality indicators
Treatment

PubMed: MeSH publication types

Review
Journal Article
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1093/ehjqcco/qcac070

Find It

Find It at U of M Libraries

Cite this

Lee, G. A., Aktaa, S., Baker, E., Gale, C. P., Yaseen, I. F., Gulati, G., Asteggiano, R., Szmit, S., Cohen-Solal, A., Abdin, A., Jurczak, W., Lopez, P. G., Sverdlov, A. L., Tocchetti, C. G., Barac, A., Parrini, I., Zamorano, P., Iakobishvili, Z., Pudil, R., ... Lopez-Fernandez, T. (2023). European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment. European Heart Journal - Quality of Care and Clinical Outcomes, 9(1), 1-7. https://doi.org/10.1093/ehjqcco/qcac070

European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment. / Lee, G. A.; Aktaa, S.; Baker, E. et al.
In: European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, No. 1, 01.01.2023, p. 1-7.

Research output: Contribution to journal › Review article › peer-review

Lee, GA, Aktaa, S, Baker, E, Gale, CP, Yaseen, IF, Gulati, G, Asteggiano, R, Szmit, S, Cohen-Solal, A, Abdin, A, Jurczak, W, Lopez, PG, Sverdlov, AL, Tocchetti, CG, Barac, A, Parrini, I, Zamorano, P, Iakobishvili, Z, Pudil, R, Badimon, L, Kirby, AM, Blaes, AH, Farmakis, D, Curigliano, G, Stephens, R, Lyon, AR & Lopez-Fernandez, T 2023, 'European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment', European Heart Journal - Quality of Care and Clinical Outcomes, vol. 9, no. 1, pp. 1-7. https://doi.org/10.1093/ehjqcco/qcac070

@article{7a9f922f7624442888268631b42be5d1,

title = "European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment",

abstract = "Aims To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. Methods and results We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy. Conclusion We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.",

keywords = "Assessment, Cancer therapy-related cardiovascular toxicity, Cardio-oncology, Outcomes, Quality indicators, Treatment",

author = "Lee, {G. A.} and S. Aktaa and E. Baker and Gale, {C. P.} and Yaseen, {Israa F.} and G. Gulati and R. Asteggiano and S. Szmit and A. Cohen-Solal and A. Abdin and W. Jurczak and Lopez, {P. Garrido} and Sverdlov, {A. L.} and Tocchetti, {C. G.} and A. Barac and I. Parrini and P. Zamorano and Z. Iakobishvili and R. Pudil and L. Badimon and Kirby, {A. M.} and Blaes, {A. H.} and D. Farmakis and G. Curigliano and R. Stephens and Lyon, {A. R.} and T. Lopez-Fernandez",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.",

year = "2023",

month = jan,

day = "1",

doi = "10.1093/ehjqcco/qcac070",

language = "English (US)",

volume = "9",

pages = "1--7",

journal = "European Heart Journal - Quality of Care and Clinical Outcomes",

issn = "2058-5225",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment

AU - Lee, G. A.

AU - Aktaa, S.

AU - Baker, E.

AU - Gale, C. P.

AU - Yaseen, Israa F.

AU - Gulati, G.

AU - Asteggiano, R.

AU - Szmit, S.

AU - Cohen-Solal, A.

AU - Abdin, A.

AU - Jurczak, W.

AU - Lopez, P. Garrido

AU - Sverdlov, A. L.

AU - Tocchetti, C. G.

AU - Barac, A.

AU - Parrini, I.

AU - Zamorano, P.

AU - Iakobishvili, Z.

AU - Pudil, R.

AU - Badimon, L.

AU - Kirby, A. M.

AU - Blaes, A. H.

AU - Farmakis, D.

AU - Curigliano, G.

AU - Stephens, R.

AU - Lyon, A. R.

AU - Lopez-Fernandez, T.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Aims To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. Methods and results We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy. Conclusion We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.

AB - Aims To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. Methods and results We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy. Conclusion We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.

KW - Assessment

KW - Cancer therapy-related cardiovascular toxicity

KW - Cardio-oncology

KW - Outcomes

KW - Quality indicators

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85144094283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85144094283&partnerID=8YFLogxK

U2 - 10.1093/ehjqcco/qcac070

DO - 10.1093/ehjqcco/qcac070

M3 - Review article

C2 - 36316010

AN - SCOPUS:85144094283

SN - 2058-5225

VL - 9

SP - 1

EP - 7

JO - European Heart Journal - Quality of Care and Clinical Outcomes

JF - European Heart Journal - Quality of Care and Clinical Outcomes

IS - 1

ER -

European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this